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Succinate dehydrogenase (SDH) deficiency is a rare autosomal 
recessive neurometabolic disorder that causes brain insult, 
neurodevelopmental delay, exercise intolerance, and cardiomyopathy.
A 25-month-old boy was referred to our neurometabolic center due 
to developmental regression after injecting the influenza vaccine 
when he was 10 months old. Magnetic resonance imaging (MRI) 
showed high signal changes in the brain white matter, and magnetic 
resonance spectroscopy (MRS) detected a high succinate peak at 2.4 
parts per million (ppm). The evaluation of urine organic acids showed 
a significant elevated succinic acid and whole exome sequencing, 
confirming SDH. Treatment with a mitochondrial cocktail was 
initiated, and remarkable improvement was observed.
SDH deficiency as a treatable neurometabolic disorder should be 
considered in any patients with developmental disorders, accompanied 
by hyperintensity in white matter (as similar to leukodystrophia). 
Further evaluation is recommended since outcomes depend on early 
diagnosis and treatment.
Keywords: Succinate dehydrogenase deficiency, Mitochondrial 
disorders, Developmental regression
Introduction
The succinate dehydrogenase (SDH) enzyme is part of respiratory 
chain complex II in the mitochondrion, and is essential for converting 
succinate to fumarate as part of the Krebs cycle. SDH deficiency 
is a rare autosomal recessive neurometabolic disorder that causes 
encephalomyopathy in children (1).
Four nuclear genes encode the four subunits of the SDH enzyme, 
namely SDHA (15 exons), SDHB (8 exons), SDHC (6 exons), and 
SDHD (4 exons), mapping onto chromosomes 5p15, 1p35-p36.1, 1q21, 
and 11q23, respectively (2). Only a few cases of SDH deficiency have 
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been reported, all resulting from mutations in the 
gene encoding the SDHA subunit (3).The first 
reported mutation in the SDHA gene was detected 
in two siblings presenting with Leigh syndrome 
and SDH deficiency (4). In a study, 23% of patients 
with respiratory-chain enzyme defects had partial 
deficiencies of succinate dehydrogenase activity 
in muscle biopsies. In most cases, this reduction 
could be detected histochemically in biopsies (5). 
This study reported a patient with SDH deficiency 
and elaborated on his treatment and follow up.
Case Presentation
A 25-month-old boy presented with a history 
of general developmental delay. He was born 
from relative parents with the gestational age of 
32 weeks, birth weight of 1500 grams, and birth 
head circumference of 32 centimeters. He had no 
family history of neurological disorders. He was 
developmentally normal until he was 10 months 
old and received an influenza vaccine. Gradually, 
he lost the ability to sit and neck holding. He was 
unable to say any words and had no history related 
to the episode of seizure. During the physical 
examination, he was alert. He could not sit and 
only had rolling from supine to prone position 
and vice versa and commando crawling. He had 
normal deep tendon reflexes (DTRs). He also had 
normal serum lactate, and the evaluation of his 
urine organic acids showed an elevated succinic 
acid (2320 mmol/mol creatinine, with normal 
range ≤343 mmol/mol creatinine). His MRI results 
showed a diffused leukodystrophic pattern in the 
periventricular white matter. Moreover, in his 
MRS results, a high succinate peak at 2.4 parts per 
million (ppm) was detected (Figure 1). Therefore, 
according to our diagnosis compatible with SDH, 
a mitochondrial cocktail including high doses 
of riboflavin, co-enzyme Q10, l-carnitine and 
thiamine, and biotin was initiated. In whole-exome 
sequencing, a homozygous missense variant was 
detected in the SDHB gene. According to the 
ClinVar database, this variant is classified as a likely 
pathogenic variant, which causes mitochondrial 
complex II deficiency. Similarly, this variant can 
be classified as a likely pathogenic variant based 
on the American College of Medical Genetics and 
Genomics (ACMG) guideline. 6-8 guideline.
After 12 months of treatment, he was able to sit 
and stand independently for 10 seconds, and was 
able to express meaningful words. Further, MRS 
showed remarkable decrease in the succinate peak 
(Figure 2).
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Figure 1. The MRS results showing a remarkable succinate peak
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Figure 2. The MRS results after 12 months of treatment showing a remarkable decrease in the succinate peak
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Genetic analysis
At first step of genetic investigations, patient’s 
blood sample were collected in EDTA containing 
tubes. Genomic DNA was extracted from 
whole blood using Blood SV-mini kit (GeneAll 
Biotechnology Co., LTD, South Korea) according 
to the manufacturer instruction. Library preparation 
was performed using Twist Human Core Exome 
kit (Twist Bioscience, USA) using manufacturer 
instruction. Sequencing of libraries was done by 
high-throughput paired-end sequencing using 
NovaSeq sequencing platform (Illumina Inc., CA, 
USA). 
Total number of reads obtained for this sample was 
57,851,802. These reads generated total sequence 
of 8,067,368,170 bases that gave an average 
throughput depth of 244X for target regions. 98.9 
percent of target regions had a coverage of more than 
1X, and 98.5 percent showed a coverage of more 
than 10X. Variant calling and filtering was done 
using Genome Analysis toolkit (GATK-v3.4.0) and 
detected variants were annotated. Proper filtering 
and then interpretation of a short list of variants 
in terms of pathogenicity was performed based on 
ACMG (American College of Medical Genetics 
and Genomics) guideline for variant interpretation 
(6). 
Above investigation resulted in detection of a 
missense variant (c.143A>T; p.D48V) in exon 
2 of SDHB gene (NM_003000.2). This variant 
was called 54 times out of total depth of 54 at this 
nucleotide position, showing a homozygous status. 
The detected homozygous missense variant 
in SDHB gene, was reported in Human Gene 
Mutation Database (HGMD) as a pathogenic 
variant in patients with complex II deficiency 
and succinate dehydrogenase-related infantile 
Leukoencephalopathy (7-8). In addition, ClinVar 
database has classified it as a likely pathogenic 
variant in its latest clinical evaluation (2018) (9). 
Multiple lines of in silico computational analysis 
(Mutation Taster, CADD, etc.) support the 
deleterious effect of this variant on the gene or gene 
product(s). The variant has very low frequency in 
population databases (ExAC, 1000G, and our local 
database). Patient’s phenotype was also consistent 
with SDHB-associated phenotypes. Having such 
information and based on ACMG guideline, this 
variant was classified as a pathogenic variant and 
diagnosis of patient’s phenotype was confirmed. 
Discussion
Inherited SDH deficiency is a rare autosomal 
recessive neurometabolic disorder that causes 
brain involvement, cardiomyopathy, and/or 
exercise intolerance. Few studies have been 
conducted on SDH deficiency. This study reported 
a patient with a clinical course and neurological 
imaging compatible with succinate dehydrogenase 
deficiency, as confirmed by a genetic study. 
In the patient, developmental milestones were in 
normal limits but gradually regressed. Furthermore, 
during physical examination, he was alert and his 
eyes’ ability to fix and follow was in normal limits. 
He had regression mostly in motor development, 
and cognition was less involved. His MRI results 
showed that signal changes were similar to 
leukodystrophia. However, he was reported to 
be alert and seizure free with normal evaluations 
related to leukodystrophia, and thus, the reliability 
of this diagnosis was questioned. As a result, we 
performed MRS, indicating a high metabolite peak 
in 2.4 ppm, which was assumed to be a succinate 
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peak. After diagnosis, treatment was initiated 
with riboflavin, coenzyme Q10, and l-carnitine. 
Moreover, a genetic study was performed for 
confirmation of the diagnosis, and as we expected, 
the result was in favor of SDH. Occupational 
therapy was useful for reducing the spasm. After 
treatment, the patient improved in different aspects 
of developmental milestones, including motor 
skills that initially improved, followed by speech 
and cognition, respectively.
In Conclusion
SDH deficiency is a treatable neurometabolic 
disorder, and its outcomes depend on early 
diagnosis and treatment. Therefore, it should be 
considered in any patients with developmental 
disorders accompanied by hyperintensity in the 
white matter (as similar to leukodystrophia).
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